Supernus Pharmaceuticals, Inc. (SUPN) News
Filter SUPN News Items
SUPN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SUPN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SUPN News From Around the Web
Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five yearsIf you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share... |
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in CanadaMONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals, |
Supernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New Yor |
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, U |
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsSupernus Pharmaceuticals ( NASDAQ:SUPN ) Third Quarter 2024 Results Key Financial Results Revenue: US$175.7m (up 14... |
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...Supernus Pharmaceuticals Inc (SUPN) reports a 26% revenue increase and raises full-year guidance, driven by robust sales of key products. |
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of 171.79% and 13.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Supernus: Q3 Earnings SnapshotSUPN) on Monday reported profit of $38.5 million in its third quarter. The Rockville, Maryland-based company said it had net income of 69 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.06 per share. |
Supernus Announces Third Quarter 2024 Financial ResultsNet sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9 million in the third quarter and first nine months of 2024, respectively. Net sales of GOCOVRI® increased 8% in the third quarter of 2024, compared to the same period in 2023. Net sales of GOCOVRI of $35.6 million and $93.9 million in the third quarter and first nine months of 2024, respectively. Total revenues were $175.7 million in the third qu |